Keros Therapeutics Inc
NASDAQ:KROS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.55
21.84
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Net Margin
Keros Therapeutics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Keros Therapeutics Inc
NASDAQ:KROS
|
634.7m USD |
26%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
397.8B USD |
4%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
175.2B USD |
19%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
150.7B USD |
28%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.4B USD |
31%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.6B USD |
32%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
84.2B AUD |
19%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.5B EUR |
43%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
52.1B USD |
1%
|
Keros Therapeutics Inc
Glance View
In the heart of the biotechnology sector lies Keros Therapeutics Inc., a company heralded for its innovative approach in addressing unfulfilled needs within hematological and musculoskeletal disorders. Established with a keen focus on advancing therapies derived from the Transforming Growth Factor-Beta (TGF-β) family of proteins, Keros aims to reshape the treatment landscape of complex diseases. Through a scientific approach anchored in proprietary technology, Keros navigates the intricate pathways of cellular growth and differentiation, thereby developing therapeutics with the potential to significantly improve patients' quality of life. Their pipeline, headlined by lead product candidates like KER-050 and KER-047, targets conditions such as myelodysplastic syndromes and fibrodysplasia ossificans progressiva, conditions that have long posed challenges to traditional medical interventions. Keros Therapeutics generates revenue primarily through the development and potential commercialization of its targeted therapies. By advancing their candidates through various clinical trial phases, Keros seeks to unlock significant market opportunities in sectors characterized by high demand and limited treatment options. Partnerships and strategic collaborations further bolster their financial backbone, as these relationships often bring in milestone payments and future royalty arrangements. The company’s model is one of strategic innovation—leveraging cutting-edge science to address critical health issues while carving out a competitive niche in the biotechnology market. This robust approach not only fuels potential breakthroughs but also charts a sustainable path toward profitability in an industry where the aspirations to alleviate complex medical conditions align seamlessly with business growth potentials.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Keros Therapeutics Inc's most recent financial statements, the company has Net Margin of 26.1%.